Log in
Sign up
Golden has been acquired by ComplyAdvantage.Read about it here ⟶
‌

US Patent 11993784 Transposition-based therapies

Patent 11993784 was granted and assigned to Saliogen Therapeutics, Inc. on May, 2024 by the United States Patent and Trademark Office.

OverviewStructured DataIssuesContributorsActivity
Is a
Patent
Patent
0
Current Assignee
‌
Saliogen Therapeutics, Inc.
0
Date Filed
March 29, 2023
0
Date of Patent
May 28, 2024
0
Patent Applicant
‌
Saliogen Therapeutics, Inc.
0
Patent Application Number
18192382
0
Patent Citations
‌
US Patent 9017967 Modular DNA-binding domains and methods of use
0
‌
US Patent 8399643 Nucleic acids encoding hyperactive PiggyBac transposases
0
‌
US Patent 8420782 Modular DNA-binding domains and methods of use
0
‌
US Patent 8470973 Modular DNA-binding domains and methods of use
0
‌
US Patent 8586526 DNA-binding proteins and uses thereof
0
‌
US Patent 8912138 DNA-binding proteins and uses thereof
0
‌
US Patent 10550407 Methods and compositions for RNA-directed target DNA modification and for RNA-directed modulation of transcription
0
‌
US Patent 10793878 Methods and compositions for RNA-directed target DNA modification and for RNA-directed modulation of transcription
0
‌
US Patent 10900054 Methods and compositions for RNA-directed target DNA modification and for RNA-directed modulation of transcription
0
‌
US Patent 10927384 DNA vectors, transposons and transposases for eukaryotic genome modification
0
•••
Patent Inventor Names
Scott McMillan
0
Joseph J. Higgins
0
Ray Tabibiazar
0
Patent Jurisdiction
United States Patent and Trademark Office
United States Patent and Trademark Office
0
Patent Number
11993784
0
Patent Primary Examiner
‌
Jennifer Dunston
0
CPC Code
‌
C07K 2319/80
0
‌
C12N 9/1241
0

Find more entities like US Patent 11993784 Transposition-based therapies

Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.
Open Query Tool
Access by API
Golden Query Tool
Golden logo
By using this site, you agree to our Terms of Service.